179 related articles for article (PubMed ID: 17096432)
1. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors.
Kobayashi K; Gupta S; Trent JC; Vauthey JN; Krishnamurthy S; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; McRae SE; Hicks ME
Cancer; 2006 Dec; 107(12):2833-41. PubMed ID: 17096432
[TBL] [Abstract][Full Text] [Related]
2. Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal tumors.
Kobayashi K; Szklaruk J; Trent JC; Ensor J; Ahrar K; Wallace MJ; Madoff DC; Murthy R; Hicks ME; Gupta S
Am J Clin Oncol; 2009 Dec; 32(6):574-81. PubMed ID: 19636238
[TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
4. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors.
Gupta S; Bedikian AY; Ahrar J; Ensor J; Ahrar K; Madoff DC; Wallace MJ; Murthy R; Tam A; Hwu P
Am J Clin Oncol; 2010 Oct; 33(5):474-80. PubMed ID: 19935383
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases.
Kamat PP; Gupta S; Ensor JE; Murthy R; Ahrar K; Madoff DC; Wallace MJ; Hicks ME
Cardiovasc Intervent Radiol; 2008; 31(2):299-307. PubMed ID: 17922160
[TBL] [Abstract][Full Text] [Related]
6. Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma.
Ahrar J; Gupta S; Ensor J; Ahrar K; Madoff DC; Wallace MJ; Murthy R; Tam A; Hwu P; Bedikian AY
Cancer Invest; 2011 Jan; 29(1):49-55. PubMed ID: 21166498
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response.
Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
Jpn J Clin Oncol; 2006 Nov; 36(11):704-11. PubMed ID: 17068083
[TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study.
Maire F; Lombard-Bohas C; O'Toole D; Vullierme MP; Rebours V; Couvelard A; Pelletier AL; Zappa M; Pilleul F; Hentic O; Hammel P; Ruszniewski P
Neuroendocrinology; 2012; 96(4):294-300. PubMed ID: 22507901
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic sarcoma to the liver with bland embolization.
Maluccio MA; Covey AM; Schubert J; Brody LA; Sofocleous CT; Getrajdman GI; DeMatteo R; Brown KT
Cancer; 2006 Oct; 107(7):1617-23. PubMed ID: 16955508
[TBL] [Abstract][Full Text] [Related]
10. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.
Steinert DM; Oyarzo M; Wang X; Choi H; Thall PF; Medeiros LJ; Raymond AK; Benjamin RS; Zhang W; Trent JC
Cancer; 2006 Apr; 106(7):1617-23. PubMed ID: 16518826
[TBL] [Abstract][Full Text] [Related]
11. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
[TBL] [Abstract][Full Text] [Related]
12. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors.
Yao KA; Talamonti MS; Nemcek A; Angelos P; Chrisman H; Skarda J; Benson AB; Rao S; Joehl RJ
Surgery; 2001 Oct; 130(4):677-82; discussion 682-5. PubMed ID: 11602899
[TBL] [Abstract][Full Text] [Related]
13. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
14. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.
Christante D; Pommier S; Givi B; Pommier R
Surgery; 2008 Dec; 144(6):885-93; discussion 893-4. PubMed ID: 19040993
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
[TBL] [Abstract][Full Text] [Related]
16. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
17. Aggressive surgery for liver metastases from gastrointestinal stromal tumors.
Shima Y; Horimi T; Ishikawa T; Ichikawa J; Okabayashi T; Nishioka Y; Hamada M; Shibuya Y; Ishii T; Ito M
J Hepatobiliary Pancreat Surg; 2003; 10(1):77-80. PubMed ID: 12827476
[TBL] [Abstract][Full Text] [Related]
18. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Blanke CD; Rankin C; Demetri GD; Ryan CW; von Mehren M; Benjamin RS; Raymond AK; Bramwell VH; Baker LH; Maki RG; Tanaka M; Hecht JR; Heinrich MC; Fletcher CD; Crowley JJ; Borden EC
J Clin Oncol; 2008 Feb; 26(4):626-32. PubMed ID: 18235122
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and outcome of resected patients for gastrointestinal stromal tumors.
Chiappa A; Zbar AP; Biffi R; Bertani E; Pace U; Pruneri G; Della Vigna P; Grassi C; Valerio M; Poldi D; Andreoni B
Hepatogastroenterology; 2007; 54(75):693-6. PubMed ID: 17591043
[TBL] [Abstract][Full Text] [Related]
20. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver.
Ruutiainen AT; Soulen MC; Tuite CM; Clark TW; Mondschein JI; Stavropoulos SW; Trerotola SO
J Vasc Interv Radiol; 2007 Jul; 18(7):847-55. PubMed ID: 17609443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
